Magazine Article | January 4, 2022

Overcoming Roadblocks Along The Cell Therapy Product Pathway

Source: Life Science Leader

By Tim Tripp

Cell and gene therapy remains a new therapeutic class with an infrastructure immersed in clinical trials. This is true even with 22 approved cellular and gene therapy products licensed through the FDA’s Office of Tissue and Advanced Therapies in the U.S. as of Oct. 19, 2021.

As more therapies receive commercial approval, biotech executives will face challenges unlike those experienced with traditional pharmaceuticals. These challenges begin with the source material and continue through therapy infusion. However, biotech executives can take steps to minimize some of these challenges throughout the cell therapy product pathway and scale efficiently.

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader